USANA Health Sciences (NYSE:USNA) Issues FY 2025 Earnings Guidance

USANA Health Sciences (NYSE:USNA - Get Free Report) updated its FY 2025 earnings guidance on Tuesday. The company provided earnings per share guidance of 2.350-3.000 for the period, compared to the consensus earnings per share estimate of 2.590. The company issued revenue guidance of $920.0 million-$1.0 billion, compared to the consensus revenue estimate of $941.6 million.

Analyst Ratings Changes

Several analysts have weighed in on USNA shares. StockNews.com cut USANA Health Sciences from a "strong-buy" rating to a "buy" rating in a report on Friday, February 14th. DA Davidson reduced their price objective on shares of USANA Health Sciences from $38.00 to $36.00 and set a "neutral" rating on the stock in a research note on Thursday, February 27th. Finally, Sidoti lowered shares of USANA Health Sciences from a "strong-buy" rating to a "hold" rating in a report on Tuesday, February 18th.

USANA Health Sciences Trading Down 0.1 %

Shares of USNA stock traded down $0.03 on Friday, hitting $27.07. The stock had a trading volume of 295,874 shares, compared to its average volume of 122,357. USANA Health Sciences has a twelve month low of $23.10 and a twelve month high of $49.78. The company has a fifty day moving average price of $27.85 and a two-hundred day moving average price of $33.17. The firm has a market cap of $510.54 million, a P/E ratio of 9.57, a PEG ratio of 0.93 and a beta of 1.00.

USANA Health Sciences (NYSE:USNA - Get Free Report) last announced its quarterly earnings results on Tuesday, April 22nd. The company reported $0.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.70 by $0.03. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. The company had revenue of $249.54 million during the quarter, compared to the consensus estimate of $243.08 million. During the same period in the prior year, the company earned $0.86 earnings per share. On average, analysts expect that USANA Health Sciences will post 2.45 earnings per share for the current year.

Insider Buying and Selling at USANA Health Sciences

In other USANA Health Sciences news, insider Joshua Foukas sold 5,732 shares of the company's stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $32.54, for a total transaction of $186,519.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Jim Brown sold 5,000 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $29.47, for a total transaction of $147,350.00. Following the transaction, the chief executive officer now directly owns 15,716 shares of the company's stock, valued at $463,150.52. This represents a 24.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 15,920 shares of company stock valued at $500,285. 0.63% of the stock is currently owned by corporate insiders.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.